| 摘要 |
The present invention relates to a method for screening a therapeutic agent for cancers by using AIMP2-DX2 and pl4/ARF interaction, more specifically, relates to a method for screening an anticancer drug that suppresses the AIMP2-DX2 and pl4/ARF interaction, which includes the steps of: (a) bringing a test substance into contact with a separated AIMP2-DX2 protein or a fragment thereof and a separated pl4/ARF protein or a fragment thereof; and (b) for a measurement to check whether or not the test substance suppresses the interaction of an AIMP2-DX2 protein or a fragment thereof and a pl4/ARF protein or a fragment thereof, selecting the test substance as a first candidate when the substance provides a decrease in the AIMP2-DX2 and pl4/ARF interaction due to a contact with the test substance as compared to a control group which has not been brought into contact with the test substance, and to a pharmaceutical composition for treating cancers which includes as an active ingredient a substance that has been screened by the screening method. The method is for screening an anticancer drug that suppresses the AIMP2-DX2 protein and pw/ARF protein interaction and is effective in manufacturing an anticancer agent by screening anticancer substances. |
